JCR Pharmaceuticals Co., Ltd. (OTCMKTS:JCRRF – Get Free Report) was the target of a significant increase in short interest in July. As of July 15th, there was short interest totaling 520,831 shares, an increase of 100.3% from the June 30th total of 260,076 shares. Based on an average trading volume of 95 shares, the short-interest ratio is presently 5,482.4 days.
JCR Pharmaceuticals Stock Performance
OTCMKTS:JCRRF opened at $3.31 on Wednesday. JCR Pharmaceuticals has a 12-month low of $3.15 and a 12-month high of $3.31. The stock has a fifty day moving average price of $3.37 and a 200 day moving average price of $3.95.
JCR Pharmaceuticals Company Profile
JCR Pharmaceuticals Co, Ltd. is a Japan-based biotechnology company specializing in the development, production and commercialization of plasma-derived products and regenerative medicine solutions. The company focuses on manufacturing high-purity plasma proteins, including human serum albumin, immunoglobulins and coagulation factors, to support a range of therapeutic applications in hematology, immunology and critical care settings.
In its plasma-derived business, JCR leverages state-of-the-art fractionation and purification processes to supply products such as intravenous immunoglobulin and albumin formulations.
See Also
- Five stocks we like better than JCR Pharmaceuticals
- UPS Just Gave Investors a Second Chance to Buy
- Welltower at 52-Week Highs—But Analysts Believe There’s More to Come
- D-Wave’s AT&T Deal Shows Quantum Computing Is Moving Beyond Theory
- Insiders Sell, Institutions Buy: The AI Trade Is Getting More Interesting
Receive News & Ratings for JCR Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JCR Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
